Zhejiang maker of pharmaceutical intermediates and APIs, including anesthetic and other fine-chemical active ingredients.
Zhejiang maker of pharmaceutical intermediates and APIs, including anesthetic and other fine-chemical active ingredients.
In one line: A small Chinese API/CDMO supplier.
Moat: none (scale). Commodity API producer competing mainly on cost and regulatory filings.
Headquarters: Taizhou, Zhejiang, China · Employees: 2,736
Size Zhejiang Hisoar Pharmaceutical (002099.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.33B, the 1700th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥5.55 on 18 Nov 2026.
Performance Over six months the shares fell 2.1%, against -19.0% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 9.2% over the last twelve months (peer median +10.0%); the operating margin is -12.7% (peer median 11.1%).
Valuation It trades at 4.7× enterprise value to sales against a peer median of 3.5× (8th most expensive of 17).
Capital Return on invested capital runs 5.9 points below its cost of capital (5.8% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.03B | CN¥1.85B | CN¥1.93B | CN¥2.14B | CN¥2.70B |
| Revenue growth | — | -4% | -10% | -21% | — |
| Gross profit | CN¥656M | CN¥378M | CN¥445M | CN¥192M | CN¥633M |
| EBITDA | n/a | CN¥228M | CN¥202M | CN¥88.9M | CN¥425M |
| Net income | -CN¥234M | -CN¥91.1M | -CN¥330M | -CN¥420M | CN¥88.0M |
| Free cash flow | -CN¥154M | -CN¥88.8M | CN¥53.2M | CN¥87.5M | -CN¥63.2M |
| Capital expenditure | CN¥90.2M | CN¥74.5M | CN¥122M | CN¥153M | CN¥179M |
| Total debt | CN¥1.53B | CN¥1.50B | CN¥1.51B | CN¥1.09B | CN¥1.35B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Hisoar Pharmaceutical 002099.SZ | $1.33B | -2% | +9% | -13% | 4.7× | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | $824M | -34% | +1% | 0% | 6.5× | n/a |
| Zhejiang Hisun Pharmaceutical 600267.SS | $2.19B | +14% | -7% | 15% | 1.7× | -9.7% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 8.0× | 13.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002099.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.3% | -2.3% | 9th lowest of 20 |
| 6-month return | -2.1% | -19.0% | 6th highest of 20 |
| Distance from 52-week high | -38.9% | -40.0% | 10th highest of 20 |
| Revenue growth (TTM) | +9.2% | +10.0% | 9th highest of 17 |
| Operating margin | -12.7% | 11.1% | 5th lowest of 17 |
| EV / Sales | 4.7× | 3.5× | 8th most expensive of 17 |
| ROIC minus cost of capital | -5.9 pp | -0.7 pp | 7th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | 4.7× | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | 3.0× | 10.2% | +18.1% |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 9.6× | 25.9% | +23.1% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 3.0× | 3.9% | +22.8% |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | 146.3× | n/a | n/a |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 4.0× | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 2.2× | -17.2% | +3.9% |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | 17.0× | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | 125.0× | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 12.8× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 2.0× | -0.4% | -1.3% |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 2.1× | -9.6% | +4.6% |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 2.3× | 2.5% | +15.5% |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 39.1× | n/a | n/a |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 4.8× | 3.4% | +27.9% |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 0.5× | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 0.8× | -18.1% | +7.0% |